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Background: Gallbladder carcinoma is a malignant tumor with a very low 5-year survival rate because of the
difficulty with its early diagnosis and the very poor prognosis of the advanced cancer state. The aims of this study
were to determine whether curcumin could induce the apoptosis of a gallbladder carcinoma cell line, GBC-SD, and
to clarify its related mechanism.
Methods: First, the anti-proliferative activities of curcumin-treated and untreated GBC-SD cells were determined
using the MTT and colony formation assays. Then, the early apoptosis of cells was detected by the annexin V/
propidium iodide double-staining assay and Hoechst 33342 staining assay. Detection of mitochondrial membrane
potential was used to validate the ability of curcumin on inducing apoptosis in GBC-SD cells. Cell cycle changes
were detected by flow cytometric analysis. Finally, the expressions of the apoptosis-related proteins or genes
caspase-3, PARP, Bcl-2, and Bax were analyzed by western blot and quantitative real time PCR assay. Statistical
analyses were performed using the Student’s t-test for comparison of the results obtained from cells with or
without curcumin treatment.
Results: The MTT assay revealed that curcumin had induced a dose- and a time-dependent decrease in cell
viability. Colony counting indicated that curcumin had induced a dose-dependent decrease in the colony
formation ability in GBC-SD cells. Cells treated with curcumin were arrested at the S phase, according to the flow
cytometric analysis. A significant induction of both the early and late phases of apoptosis was shown by the
annexin V-FITC and PI staining. Morphological changes in apoptotic cells were also found by the Hoechst 33342
staining. After treatment with curcumin fluorescence shifted from red to green as ΔΨm decreased. Furthermore,
western blot and quantitative real time PCR assays demonstrated that the curcumin induced apoptosis in GBC-SD
cells by regulating the ratio of Bcl-2/Bax and activating the expression of cleaved caspase-3.
Conclusions: Taken together, the results indicate that curcumin may be a potential agent for the treatment of
gallbladder cancer.
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Gallbladder carcinoma is one of the most common malig-
nant tumors of the biliary system and is the fifth most com-
mon malignancy of the gastrointestinal tract [1-2]. Early
gallbladder carcinoma is asymptomatic or manifests only as
an abdominal discomfort. Some patients can develop the
symptom of acute or chronic cholecystitis, which is easy to
ignore or miss. In the later period, patients can develop
abdominal pain, jaundice, and angular, but most of the pa-
tients have no surgical opportunities. The prognosis of ad-
vanced gallbladder carcinoma is very poor, [3-5] and the
5-year survival rate is only about 5% [6]. So far, surgical re-
section is the only treatment that offers a hope for cure [7].
Moreover, the majority of patients have frequent recur-
rences following surgery and unsatisfactory results follow-
ing chemotherapy or radiotherapy [8]. Therefore, more
research about the occurrence of gallbladder carcinoma
and the mechanism of its development, as well as find-
ing effective treatments and drugs, is an important need.
Curcumin, a phenolic compound present in Zingiberaceae
Curcuma longa, rhizoma zedoariae, turmeric, etc., has
been shown to have anticarcinogenic [9-11] and anti-
inflammatory properties [12], including an inhibitory effect
on the production of various cytokines. Curcumin has
attracted much attention because of its low price and low
toxicity, as well as its wide pharmacological and potential
anticancer effects. It is believed that the anticancer mech-
anism of curcumin is mainly in inducing the apoptosis of
cancer cells [13-15] and suppressing metastasis [16-18].
The apoptosis induced by curcumin is due to the activa-
tion of a multi-signal transduction pathway. Curcumin in-
duces apoptosis in breast cancer cell lines, and the
activation of apoptosis was confirmed by PARP-1 cleavage
and by the increased ratio between the pro-apoptotic Bax
and the anti-apoptotic Bcl-2 proteins [19]. Moreover,
apigenin and curcumin synergistically induced cell death
and apoptosis and also blocked cell cycle progression at
the G2/M phase of A549 cells [20]. Although curcumin
has been found to induce apoptosis in several types of
cancers, the molecular apoptotic mechanisms of curcumin
in the gallbladder carcinoma cell line GBC-SD have not
previously been investigated.
The goals of this study were to determine whether
curcumin could induce apoptosis in GBC-SD cells and
to clarify the related mechanism, which may offer a
promising new approach in the effective treatment of
gallbladder carcinoma.
Results
Effect of curcumin on the viability of GBC-SD cells
The effects of curcumin on the growth of human GBC-
SD cells in vitro were tested. As shown in Figure 1(A),
after treatment for 24, 48, and 72 h, curcumin induced a
dose- and a time-dependent decrease in the viability ofthe GBC-SD cells, as analyzed by the MTT assay. As
shown in Figure 1(B), the ability of GBC-SD cells to
form colonies in the presence of curcumin was detected
with the flat plate colony formation assay. The colony
count indicated that curcumin had induced a dose-
dependent decrease in the colony formation ability.
Moreover, statistical analysis demonstrated that the
mean sizes of the control colonies were larger than those
of the curcumin-treated group. The findings support the
fact that curcumin may exert a significant influence on
GBC-SD cell proliferation.
Effect of curcumin on cell cycle distribution in GBC-SD cells
To assess whether curcumin affects cell cycle progres-
sion, flow cytometric analysis was carried out. The re-
sults showed a significant decrease in the number of
cells in the proliferative G0/G1 phase and a significant
increase in the number of cells in the S phase, after 48 h
of treatment with curcumin (Figure 2). These results in-
dicate that curcumin arrests the cell cycle at the S phase.
Effect of curcumin on apoptosis in GBC-SD cells
To confirm these results, we evaluated the effects of
curcumin on apoptosis in GBC-SD cells by using
annexin V-FITC and propidium iodide staining. Normal
live cells, phosphatidyl serine (PS) is located on the cyto-
plasmic surface of the cell membrane. However, in apop-
totic cells, PS is translocated from the inner to the outer
leaflet of the plasma membrane, thus exposing PS to the
external cellular environment. The human anticoagulant,
annexin-V, is a 35–36 kDa Ca2+−dependent phospho-
lipid binding protein that has a high affinity for PS.
Annexin-V labeled with a fluorophore or biotin can
identify apoptotic cells by binding to PS exposed on the
outer leaflet.In addition, the red-fluorescent propidium
iodide (PI) nucleic acid binding dye is impermeant to
live cells and apoptotic cells, but stains dead cells with
red fluorescence, binding tightly to the nucleic acids in
the cell. After staining a cell population with annexin V
and PI, apoptotic cells show green fluorescence, dead
cells show red and green fluorescence, and live cells
show little or no fluorescence. These populations can
easily be distinguished using a flow cytometer. In the
scatter plot of double variable flow cytometry, Q3
quadrant(FITC - / PI -) shows living cells; Q2 quadrant
(FITC + /PI + ) stands for late apoptotic cells; and Q4
quadrant(FITC + /PI -) represents early apoptotic cells.
As assessed by flow cytometry and shown in Figure 3(A),
a marked dose-dependent increase in both the early and
late stages of apoptosis was obvious in GBC-SD cells
after curcumin treatment compared with control cells.
Morphological changes in the apoptotic cells were
revealed by the Hoechst 33342 staining, as shown in
Figure 3(B). In the untreated GBC-SD cells, the nuclei
Figure 1 Curcumin inhibits the proliferation of GBC-SD cells. (A) Cells were treated with varying concentrations of curcumin, and the cell
proliferation and IC50 were determined by MTT assay on days 1, 2, and 3. Each value represents the mean ± SD (n = 3). (B) Curcumin suppressed
colony formation of GBC-SD cells. Cells were treated with curcumin (0.75, 1.5, and 3 μmol/L) and were allowed to form colonies in fresh medium for
14 days. The photomicrographic difference (Left panel) and influence of colonies (mean ± SD, n = 3) (Right panel) in colony formation are shown.
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group treated with curcumin, bright chromatin conden-
sation and nuclear fragmentation were observed, the
rates of which increased in a dose-dependent manner.
Effects of curcumin on mitochondrial membrane
potential(ΔΨm)
To validate the ability of curcumin on inducing apoptosis
in GBC-SD cells, we performed a cellular functional assay.
JC-1 probe is a fluorescent cationic dye that can selectively
accumulate into mitochondria by electrochemical gradientand changes color from red to green as ΔΨm decreases.
As illustrated in Figure 3(C), untreated GBC-SD cells
exhibited red fluorescence. After treatment with.
Effect of curcumin on the signal pathway of caspase and
Bcl-2 family members in GBC-SD cells
To investigate the possible mechanism of curcumin’s
apoptotic effect on the GBC-SD cells, the expressions
of apoptosis-related proteins (viz., PARP, caspase-3,
Bax, and Bcl-2) were assessed by western blot analysis.
As illustrated in Figure 4(A), treatment with curcumin
Figure 2 Curcumin induces S-phase arrest in GBC-SD cells. Cells were treated with , 3.75, 7.5 and 15 μmol/L curcumin for 48 h and the DNA
content was analyzed by flow cytometry. The percentage of cells in the G1, S, and G2/M phases of the cell cycle are shown. These results were
from 1 representative experiment of 3 independent trials.
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of Bax, cleaved caspase-3, and PARP, which may be partially
responsible for the apoptotic tendency of the GBC-SD cells.
Real-time quantitative PCR was used to quantify the levels
of Bax and Bcl-2 mRNA. Figure 4(B) showed that the ex-
pression of Bax mRNA was upregulated in the curcumin
treatment group while Bcl-2 mRNA was downregulated.
Discussion
To the best of our knowledge, this is the first study to reveal
the ability of the natural compound curcumin to induce
apoptosis in GBC-SD cells. In recent years, studies have
shown that curcumin can inhibit the growth of a variety of
tumor cells [9,21,22], as well as induce cell differentiation
[23] and apoptosis in some tumors [24-27]. Curcumin can
also be used as a natural antitumor drug [28]. Here, we
have shown the biochemical and molecular mechanisms of
apoptosis induction by curcumin in GBC-SD cells.
Curcumin manifests its antitumor effect through the in-
duction of cell apoptosis in vitro. Our experiment showed
a significant inhibition of cell proliferation in a dose- and
time-dependent manner, thereby suggesting that treat-
ment with curcumin inhibited the growth and reduced
the viability of GBC-SD cells. The cell apoptosis experi-
ment showed that curcumin had the biological activity of
inducing tumor cell apoptosis. We used flow cytometry to
detect the cell cycle, and the results showed a significant
decrease in the number of cells in the proliferative G0/G1
phase and a significant increase in the number of cells in
the S phase, after 48 h of treatment with curcumin. Theresult suggested that curcumin could block cells in the S
phase, which prevented DNA from replicating properly,
thus inhibiting tumor growth.
Cell apoptosis is an autonomous cell death process,
which can be induced by a variety of drugs and physical
and chemical factors. The induction of apoptosis has
been described as a standard and best strategy in anti-
cancer therapy [29,30]. The family of cysteine-containing
aspartate-specific proteases (caspase) contains many
members that are closely related with cell apoptosis
[31,32]. So far, 10 members have been identified in
humans. Caspase-3, a protein on the common path of cell
apoptosis, is one of the most important members and the
key executor of cell apoptosis. Caspase-3 usually exists in
the cytoplasm in the form of an inactive zymogen. When
activated by the many external apoptosis signals, caspase-
3 can induce the inactivation of many key proteases in the
cytoplasm, cell nucleus, and cytoskeleton, and finally
cause the apoptosis of cells. In our study, the results
showed that the change of caspase-3 expression was in ac-
cordance with the tendency of changes in cell apoptosis.
The cleavage of PARP was increased accordingly. The
Bcl-2 gene family is one of the best studied of the anti-
apoptosis genes, and according to the members’ different
biological effects, it is divided mainly into the Bax, Bcl-2,
and Bid proteins. Among them, the apoptosis-promoting
protein Bax and the anti-apoptotic protein Bcl-2 play an
important role in regulating cell apoptosis [33,34]. The
occurrence and severity of apoptosis depends on the ratio of
Bcl-2/Bax [35]. When this ratio is reduced, the caspase
Figure 3 (See legend on next page.)
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Figure 3 Curcumin induces apoptosis in GBC-SD cells. (A) Cells were incubated with curcumin (3.75, 7.5, and 15 μmol/L) for 48 h, followed
by staining with annexin-V/PI. The Q3 quadrant (annexin V−/PI−), Q4 quadrant (annexin V+/PI−) and Q2 quadrant (annexin V+/PI+) indicate the
percentage of normal cells, early apoptosis and late apoptosis, respectively. (B) Apoptotic nuclear morphology changes induced by curcumin
(3.75, 7.5, and 15 μmol/L) treatment for 48 h, were observed by Hoechst 33342 staining in GBC-SD cell lines. (C) Analysis of the mitochondrial
membrane potential (ΔΨm). GBC-SD cells were treated with curcumin (3.75, 7.5, and 15 μmol/L) for 48h and then stained with JC-1. Red
fluorescence represents mitochondria with intact membrane potential. Green fluorescence represents de-energized mitochondria. Images were
taken with a fluorescence microscope.
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blot assay, it was found that the expression of Bcl-2
was reduced and that of Bax was promoted in GBC-SD cells
treated with curcumin, thus decreasing the Bcl-2/Bax ratio
significantly.
Conclusion
In conclusion, this study suggests that curcumin inhibits
the proliferation of GBC-SD cells and arrests the cell
cycle in the S phase. Curcumin induces GBC-SD cell
apoptosis mainly by activating the Bcl-2 and caspase-3
pathways. Other apoptotic mechanisms remain to be
researched further.
Methods
Cell lines and culture
GBC-SD cells were purchased from the Shanghai Cell
Institute Country Cell Bank. The cells were cultured in
high-glucose DMEM (Gibco, USA) supplemented with
10% fetal bovine serum (Gibco, USA), 100 μg/mL
streptomycin and 100 U/mL penicillin (Hyclone, USA),
at 37°C, under a 5.0% CO2 atmosphere.
Drugs and antibodies
The curcumin was purchased from Sigma-Aldrich
(St. Louis, USA), dissolved in DMSO as a stock concen-
tration of 100 mmol/L, and stored in the dark at −20°C.
Figure 5 shows the chemical structural of curcumin. The
final curcumin concentrations used for the different ex-
periments were prepared by diluting the stock solution
with high-glucose DMEM. The antibodies used for
western blotting were as follows: rabbit anti-caspase-3,
anti-Bcl-2, anti-Bax, anti-PARP, anti-tubulin and mouse




Drug sensitivity was determined using the MTT assay
[36]. Briefly, cells were trypsinized and plated into 96-
well plates (Corning, USA) at a density of 5 × 103 cells
per well. The cells were cultured overnight and then
replenished with fresh medium containing various con-
centrations (0, 3.75, 7.5, 15, 30, and 60 μmol/L) ofcurcumin for 24, 48, and 72 h. Thereafter, 20 μL of
MTT (Sigma-Aldrich) dissolved in PBS at 5 mg/mL was
added directly to all the wells, and the plates were incu-
bated for 4 h at 37°C. The formazan crystals that formed
were dissolved in 100 μL of DMSO after removal of the
supernatant. The optical density was recorded at 490 nm
on a microplate reader (Bio-Tek, USA). The results rep-
resent the average of 3 independent experiments done
over multiple days. The percentage of cell viability was
calculated as follows:




Cells in the logarithmic growth phase were digested into
a single-cell suspension with a trypsin-EDTA (Gibco,
USA) solution, and then 2 mL of the cell suspension was
seeded onto 6-well plates (Corning, USA) at a density of
200 cells/mL. After adherence, the cells were treated
with curcumin (0.75, 1.5, and 3 μmol/L) for 48 h and
then cultured for 15 days. Thereafter, the cells were fixed
with 10% formalin and stained with 0.1% crystal violet
(Sigma-Aldrich). After washing, the plates were air dried,
and digital images were taken of stained single clones
observed under a microscope (Leica, Germany). The
results represent the average of 3 independent experi-
ments done over multiple days.
Cell cycle analysis
GBC-SD cells were treated with curcumin (3.75, 7.5, and
15 μmol/L) for 48 h. Then, the cells were collected and
fixed with cold 70% ethanol and stored at −20°C. The
cells were then washed and resuspended in cold PBS
and incubated at 37°C for 30 min with 10 mg/mL RNase
and 1 mg/mL propidium iodide (Sigma-Aldrich). DNA
content analysis was performed by flow cytometry (BD,
San Diego, USA). The percentage of cells in the different
cell cycle phases was determined using the Cell Quest
acquisition software (BD Biosciences).
Flow cytometric analysis of cell apoptosis
The annexin V/propidium iodide assay was performed
according to the manufacturer’s recommendation
Figure 5 Chemical structure of curcumin. The molecular formula
of curcumin is C21H20O6 and its molecular weight is 368.37.
Figure 4 Curcumin induces the activation of apoptosis-related proteins and mRNA in GBC-SD cells. (A) After treatment with curcumin (0,
3.75, 7.5, and 15 μmol/L) for 48h, cell lysates were prepared and western blot analysis was performed against Bcl-2, Bax, caspase-3, and PARP. β-
Actin and β-tubulin were used as a loading control. (B) Quantitative real-time PCR was used to examine the expression of Bax and Bcl-2 mRNA.
Curcumin upregulated mRNA expression of Bax, and downregulated mRNA expression of Bcl-2.
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into 6-well plates (Corning, USA) and incubated for
48 h with curcumin (3.75, 7.5, and 15 μmol/L). In brief,
the cells were collected and then were washed with
cold PBS, centrifuged, resuspended in 100 ul of bind-
ing buffer containing 2.5 ul FITC conjugated annexin-v
and 1ul 100 ug/ml PI and incubated for 15 mins at
room temperature in the dark. A total of at least
10 000 events were collected and analyzed by flow
cytometry (BD, San Diego, USA).
Detection of morphological apoptosis with Hoechst
33342 staining
After treatment with curcumin (3.75, 7.5, and 15 μmol/L)
for 48 h, the GBC-SD cells were washed with PBS and fixed
with methanol:acetic acid (3:1) for 15 min at room
temperature. Fixed cells were washed with PBS and stained
with 5 μg/mL of Hoechst 33342 stain for 10 min. Changes
in the nuclei of cells after staining with Hoechst 33342 were
observed using a fluorescence microscope (Leica, Germany).
Detection of mitochondrial membrane potential(ΔΨm)
variation with fluorescence microscopy
The ΔΨm was analyzed by fluorescence microscopy
using the 5,50,6,60-tetrachloro-1,10,3,30-tetraethylben
zimidazolcarbocyanine iodide (JC-1) probe. After
treatment with curcumin (3.75, 7.5, and 15 μmol/L) for
48 h, 5ul of the JC-1 staining solution(Beyotime,China)
per ml culture of medium was added to each well and
samples were then incubated in 5% CO2 incubator at
37°C for 20 min protected from light. After washingtwice with buffer solution, GBC-SD cells were analyzed
by using a fluorescence microscope (Leica, Germany).
Reverse transcription and quantitative real-time
polymerase chain reaction (qPCR)
Quantitative PCR was performed as previously described
[37] qPCR was used to quantify the expression of BCL2
and Bax mRNA in the experimental groups. GBC-SD cells
were treated with curcumin (3.75, 7.5, and 15 μmol/L) for
48 h. Total RNA was isolated using the RNA easy kit
(Invitrogen, USA). First strand cDNA was synthesized from
500 ng total RNA using a PrimeScript® Reverse Transcript-
ase (TaKaRa, Japan). Quantitative real-time PCR was
performed in a reaction volume of 20 μl including 2 μl
cDNA. The primer sequences were as follows: BCL2 (for-
ward-5’-CAA ATG CTG GAC TGA AAA ATT GTA-3’,
reverse-5’-TAT TTT CTA AGG ACG GCA TGA TCT-3’),
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reverse-5’-AGG AAG TCC AGT GTC CAG C-3’) and
GAPDH (forward-5’-AAG CTC ATT TCC TGG TAT
GACA-3’, reverse-5’-TCT TAC TCC TTG GAG GCC
ATGT-3’). PCR conditions were as follows: 95°C for 30sec
followed by 40 cycles at 95°C for 5 sec, 60°C for 34 sec.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as an internal reference gene to normalize the
expression of apoptotic genes. Relative quantification of
apoptosis-related genes was analyzed by the comparative
threshold cycle (Ct) method. For each sample, the Ct value
of the apoptotic gene was normalized using the formula:
ΔCt = Ct (apoptotic genes) - Ct (GAPDH). To determine
relative expression levels, the following formula was used:
ΔΔCt = ΔCt (treated) - ΔCt (control). The value was used
to plot the expression of apoptotic genes using the formula
2−ΔΔCt.
Western blot analysis
Western blot was performed as previously described [38].
Breafly, GBC-SD cells were treated with various concentra-
tions of curcumin (3.75, 7.5, and 15 μmol/L) for 48 h and
then lysed in a sample buffer, followed by denaturation.
The total protein concentration of the cell extracts was
determined using the bicinchoninic acid assay system
(Beyotime, China) with BSA as a standard. Equal quantities
(80 μg protein per lane) of total proteins were separated by
SDS-PAGE (8%, 12% gels) under reducing conditions. The
proteins were then electrophoretically transferred to nitro-
cellulose membranes. The membranes were blocked with
5% skimmed milk, and incubated with anti-caspase-3, anti-
Bcl-2, anti-Bax, anti-PARP, anti-β-actin and anti-β-tubulin
antibodies, respectively (1:1000; Cell Signaling Technology)
at 4°C overnight. This was followed by an incubation with
goat anti-rabbit/anti-mouse secondary antibody conjugated
with horseradish peroxidase (1:5000; Abcam). An equal
loading of each lane was evaluated by immunoblotting the
same membranes with β-actin antibodies after the detach-
ment of previous primary antibodies. Photographs were
taken and the optical densities of the bands were scanned
and quantified with the Gel Doc 2000 (BioRad, USA).
Statistical analysis
All values are expressed as the mean ± SD and they were
analyzed by the Student’s t-test using SPSS version 13.0 soft-
ware. A p-value of less than 0.05 was considered significant.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TZJ and LTY were responsible for the design of the experiments. LTY
contributed to the execution of experiments, data statistics, and writing of
the manuscript. JL participated in performing the experiment, and in the
mapping and submission of the manuscript. LYB and TZJ were responsiblefor the funding application, and supervision and management of the project.
All authors have contributed to and approved the final manuscript.Acknowledgments
This study was supported by the National Natural Science Foundation of China
(No. 81172026, 81272402, and 81172029), Foundation of Shanghai Outstanding
Academic Leaders (No. 11XD1403800), National High Technology Research and
Development Program (863 Program) (No. 2012AA022606), Post-doctoral
Research Foundation of China (No. 2012M511107), Foundation for Interdisciplinary
Research of Shanghai Jiaotong University (No. YG2011ZD07), Shanghai Science
and Technology Commission Inter-governmental International Cooperation
Project (No. 12410705900), and Post-doctoral Research Program of Shanghai (No.
12R21415300).
Author details
1Laboratory of General Surgery and Department of General Surgery, Xinhua
Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine, No.
1665 Kongjiang Road, Shanghai 200092, China. 2Department of General
Surgery, Changshu Hospital, Affiliated to Suzhou University, Changshu, China.
3Research Institute of Biliary Tract Disease, Affiliated to Shanghai Jiao Tong
University, School of Medicine, No. 1665 Kongjiang Road, Shanghai 200092,
China.
Received: 27 April 2013 Accepted: 23 June 2013
Published: 26 June 2013References
1. Kaza RK, Gulati M, Wig JD, Chawla YK: Evaluation of gall bladder carcinoma
with dynamic magnetic resonance imaging and magnetic resonance
cholangiopancreatography. Australas Radiol 2006, 50(3):212–217.
2. Tan Z, Li M, Wu W, Zhang L, Ding Q, Wu X, Mu J, Liu Y: NLK is a key
regulator of proliferation and migration in gallbladder carcinoma cells.
Mol Cell Biochem 2012, 369(1–2):27–33.
3. Wang JW, Peng SY, Li JT, Wang Y, Zhang ZP, Cheng Y, Cheng DQ, Weng
WH, Wu XS, Fei XZ, et al: Identification of metastasis-associated proteins
involved in gallbladder carcinoma metastasis by proteomic analysis and
functional exploration of chloride intracellular channel 1. Cancer Lett
2009, 281(1):71–81.
4. Wang JD, Shi WB, Shen J, Zhuang PY, Quan ZW, Wang XF, Zhou XP, Li SG, Liu YB,
Yang Y: Evaluation of two modified ECF regimens in the treatment of
advanced gallbladder cancer. Med Oncol 2011, 28(Suppl 1):S295–300.
5. Dong P, He XW, Gu J, Wu WG, Li ML, Yang JH, Zhang L, Ding QC, Lu JH,
Mu JS, et al: Vimentin significantly promoted gallbladder carcinoma
metastasis. Chin Med J (Engl) 2011, 124(24):4236–4244.
6. Miller G, Jarnagin WR: Gallbladder carcinoma. Eur J Surg Oncol 2008,
34(3):306–312.
7. Shimada K, Nara S, Esaki M, Sakamoto Y, Kosuge T, Hiraoka N: Extended
right hemihepatectomy for gallbladder carcinoma involving the hepatic
hilum. Br J Surg 2011, 98(1):117–123.
8. Malka D, Boige V, Dromain C, Debaere T, Pocard M, Ducreux M: Biliary tract
neoplasms: update 2003. Curr Opin Oncol 2004, 16(4):364–371.
9. Ye F, Zhang GH, Guan BX, Xu XC: Suppression of esophageal cancer cell
growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin.
World J Gastroenterol 2012, 18(2):126–135.
10. Saha A, Kuzuhara T, Echigo N, Fujii A, Suganuma M, Fujiki H: Apoptosis of
human lung cancer cells by curcumin mediated through up-regulation
of "growth arrest and DNA damage inducible genes 45 and 153".
Biol Pharm Bull 2010, 33(8):1291–1299.
11. Kumaravel M, Sankar P, Latha P, Benson CS, Rukkumani R: Antiproliferative
effects of an analog of curcumin in Hep-2 cells: a comparative study
with curcumin. Nat Prod Commun 2013, 8(2):183–186.
12. Guimaraes MR, Coimbra LS, de Aquino SG, Spolidorio LC, Kirkwood KL, Rossa C Jr:
Potent anti-inflammatory effects of systemically administered curcumin
modulate periodontal disease in vivo. J Periodontal Res 2011, 46(2):269–279.
13. Debnath S, Saloum D, Dolai S, Sun C, Averick S, Raja K, Fata JE: Dendrimer-
curcumin. A Water Soluble and Effective Cytotoxic Agent against Breast
Cancer Cell Lines. Anticancer Agents Med Chem: Conjugate; 2013.
14. Faiao-Flores F, Suarez JA, Maria-Engler SS, Soto-Cerrato V, Perez-Tomas R,
Maria DA: The curcumin analog DM-1 induces apoptotic cell death in
melanoma. Tumour Biol 2013, 34(2):1119–1129.
Liu et al. Cancer Cell International 2013, 13:64 Page 9 of 9
http://www.cancerci.com/content/13/1/6415. Wang WZ, Li L, Liu MY, Jin XB, Mao JW, Pu QH, Meng MJ, Chen XG, Zhu JY:
Curcumin induces FasL-related apoptosis through p38 activation in human
hepatocellular carcinoma Huh7 cells. Life Sci 2013, 92(6–7):352–358.
16. Zhang CY, Zhang L, Yu HX, Bao JD, Lu RR: Curcumin inhibits the metastasis of
K1 papillary thyroid cancer cells via modulating E-cadherin and matrix
metalloproteinase-9 expression. Biotechnol Lett 2013, 35(7):995–1000.
17. Cheng TS, Chen WC, Lin YY, Tsai CH, Liao CI, Shyu HY, Ko CJ, Tzeng SF,
Huang CY, Yang PC, et al: Curcumin-targeting pericellular serine protease
matriptase role in suppression of prostate cancer cell invasion, tumor
growth, and metastasis. Cancer Prev Res (Phila) 2013, 6(5):495–505.
18. Liu L, Sun L, Wu Q, Guo W, Li L, Chen Y, Li Y, Gong C, Qian Z, Wei Y:
Curcumin loaded polymeric micelles inhibit breast tumor growth and
spontaneous pulmonary metastasis. Int J Pharm 2013, 443(1–2):175–182.
19. Masuelli L, Benvenuto M, Fantini M, Marzocchella L, Sacchetti P, Di Stefano E,
Tresoldi I, Izzi V, Bernardini R, Palumbo C, et al: Curcumin induces apoptosis in
breast cancer cell lines and delays the growth of mammary tumors in neu
transgenic mice. J Biol Regul Homeost Agents 2013, 27(1):105–119.
20. Choudhury D, Ganguli A, Dastidar DG, Acharya BR, Das A, Chakrabarti G:
Apigenin shows synergistic anticancer activity with curcumin by binding
at different sites of tubulin. Biochimie 2013, 95(6):1297–1309.
21. Subramaniam D, Ponnurangam S, Ramamoorthy P, Standing D, Battafarano
RJ, Anant S, Sharma P: Curcumin induces cell death in esophageal cancer
cells through modulating Notch signaling. PLoS One 2012, 7(2):e30590.
22. Han X, Xu B, Beevers CS, Odaka Y, Chen L, Liu L, Luo Y, Zhou H, Chen W,
Shen T, et al: Curcumin inhibits protein phosphatases 2A and 5, leading
to activation of mitogen-activated protein kinases and death in tumor
cells. Carcinogenesis 2012, 33(4):868–875.
23. Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G, Liu A, Wang TC, Yang CS:
Curcumin induces the differentiation of myeloid-derived suppressor cells
and inhibits their interaction with cancer cells and related tumor
growth. Cancer Prev Res (Phila) 2012, 5(2):205–215.
24. Quitschke WW: Curcuminoid binding to embryonal carcinoma cells:
reductive metabolism, induction of apoptosis, senescence, and
inhibition of cell proliferation. PLoS One 2012, 7(6):e39568.
25. Sahu RP, Batra S, Srivastava SK: Activation of ATM/Chk1 by curcumin
causes cell cycle arrest and apoptosis in human pancreatic cancer cells.
Br J Cancer 2009, 100(9):1425–1433.
26. Miller M, Chen S, Woodliff J, Kansra S: Curcumin (diferuloylmethane) inhibits
cell proliferation, induces apoptosis, and decreases hormone levels and
secretion in pituitary tumor cells. Endocrinology 2008, 149(8):4158–4167.
27. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP:
Curcumin inhibits the proteasome activity in human colon cancer cells
in vitro and in vivo. Cancer Res 2008, 68(18):7283–7292.
28. Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y,
Padhye S, et al: Curcumin analogue CDF inhibits pancreatic tumor
growth by switching on suppressor microRNAs and attenuating EZH2
expression. Cancer Res 2012, 72(1):335–345.
29. Kelly PN, Strasser A: The role of Bcl-2 and its pro-survival relatives in
tumourigenesis and cancer therapy. Cell Death Differ 2011, 18(9):1414–1424.
30. Strasser A, Cory S, Adams JM: Deciphering the rules of programmed cell death to
improve therapy of cancer and other diseases. EMBO J 2011, 30(18):3667–3683.
31. Kroemer G, Galluzzi L, Brenner C: Mitochondrial membrane
permeabilization in cell death. Physiol Rev 2007, 87(1):99–163.
32. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV,
Dawson TM, Dawson VL, El-Deiry WS, Fulda S, et al: Molecular definitions
of cell death subroutines: recommendations of the Nomenclature
Committee on Cell Death 2012. Cell Death Differ 2012, 19(1):107–120.
33. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN: Bcl-2/Bax: a rheostat
that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol
1993, 4(6):327–332.
34. Lindsay J, Esposti MD, Gilmore AP: Bcl-2 proteins and mitochondria–
specificity in membrane targeting for death. Biochim Biophys Acta 2011,
1813(4):532–539.
35. Walensky LD: BCL-2 in the crosshairs: tipping the balance of life and
death. Cell Death Differ 2006, 13(8):1339–1350.
36. Plumb JA: Cell sensitivity assays: the MTT assay. Methods Mol Med 2004,
88:165–169.
37. Dong P, Zhang Y, Gu J, Wu W, Li M, Yang J, Zhang L, Lu J, Mu J, Chen L, et al:
Wogonin, an active ingredient of Chinese herb medicine Scutellaria
baicalensis, inhibits the mobility and invasion of human gallbladdercarcinoma GBC-SD cells by inducing the expression of maspin.
J Ethnopharmacol 2011, 137(3):1373–1380.
38. Quan Z, Gu J, Dong P, Lu J, Wu X, Wu W, Fei X, Li S, Wang Y, Wang J, et al:
Reactive oxygen species-mediated endoplasmic reticulum stress and
mitochondrial dysfunction contribute to cirsimaritin-induced apoptosis
in human gallbladder carcinoma GBC-SD cells. Cancer Lett 2010,
295(2):252–259.
doi:10.1186/1475-2867-13-64
Cite this article as: Liu et al.: Curcumin induces apoptosis in gallbladder
carcinoma cell line GBC-SD cells. Cancer Cell International 2013 13:64.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
